Clinigen, a specialist pharmaceutical services business based in Burton, has acquired Kinesys Consulting, a provider of strategic regulatory affairs, regulatory/medical writing, and medical devices services for the pharmaceutical and biotechnology industries. This strategic acquisition enhances Clinigen’s ability to offer clients comprehensive high-value services throughout the drug development and commercialization lifecycle.
Moreover, Kinesys brings valuable expertise in regulatory strategy and execution for drugs and medical devices, complementing Clinigen’s existing capabilities in regulatory affairs, pharmacovigilance, medical information, clinical trial services, licensed and unlicensed distribution, managed access, and commercialization. The Kinesys team, along with its respected scientific and regulatory advisory board, will integrate into Clinigen’s Lifecycle Services division.
Clinigen CEO Jerome Charton expressed, “At Clinigen, we are committed to ensuring universal access to necessary treatments. This acquisition aligns Clinigen’s dedication to healthcare equity with Kinesys’ specialized expertise, solidifying Clinigen’s position as a leader in life sciences.”
Co-founder of Kinesys Consulting Elaine Murphy emphasized, “At Kinesys, we specialize in guiding clients through regulatory strategy and execution for drugs and medical devices, as well as providing high-quality medical/regulatory writing services. By joining Clinigen, we look forward to providing a seamless path for our existing and new clients to navigate regulatory hurdles and achieve successful market access.”
Co-founder Gerry McGettigan further added, “Clinigen’s commitment to enhancing access to essential treatments globally makes them the ideal partner to propel Kinesys into its next chapter. Collaborating with Clinigen, we can accelerate patient access to life-saving treatments on a global scale.”
Both Elaine Murphy and Gerry McGettigan will continue within the business to ensure a smooth transition and contribute their expertise to Clinigen’s new Lifecycle Services division.
